MannKind Corp., the biotechnology company run by billionaire inventor Alfred Mann, failed to win approval from U.S. regulators to market its inhaled insulin drug, Afrezza, for people with diabetes.

Read more here:
MannKind’s Insulin Afrezza Fails to Win Approval (Update2)